Search Results

Medtronic's CoreValve TAVR System Shows Lower Structural Valve Deterioration Versus SAVR

April 4, 2022—Michael J. Reardon, MD, presented a study, “Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the Core Valve United States Pivotal and SURTAVI Trials," at ACC.22, the American College of Cardiology (ACC) 71st annual scientific session, held April 2-4 in Washington, DC.

Analysis of CoreValve Trial Supports TAVR Versus SAVR for Intermediate-Risk Patients

August 19, 2016—In a study by Michael J. Reardon, MD, et al, the investigators concluded that self-expanding transcatheter aortic valve replacement (TAVR) compares favorably with surgical aortic valve replacement (SAVR) in high-risk patients with predictive scores that are traditionally considered intermediate risk. The study is available online ahead of print in the Journal of the American Medical Association: Cardiology (JAMA: Cardiology).

REPRISE III Trial Compares Mechanical- Versus Self-Expanding TAVR Devices

March 5, 2019—Two-year outcomes from the REPRISE III randomized clinical trial were published online by Michael J. Reardon, MD, et al in Journal of the American Medical Association (JAMA): Cardiology.

Two-Year Data Published From United States Pivotal Trial of Medtronic's CoreValve TAVR System

July 10, 2015—Two-year outcomes from the United States pivotal trial for the self-expanding CoreValve transcatheter aortic valve replacement (TAVR) system (Medtronic plc) were published by Michael J. Reardon, MD, et al in the Journal of the American College of Cardiology (JACC; 2015;66:113–121).

Two-Year EVOLUT Data Support TAVR in Low-Risk Patients

March 16, 2019—At the American College of Cardiology's (ACC) 68th Annual Scientific Session, being held March 16–18 in New Orleans, Louisiana, the 24-month findings from the EVOLUT Low-Risk trial will be presented on March 17 by senior investigator Michael J. Reardon, MD. The trial is comparing self-expanding transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) in patients at low surgical risk. The study, which was funded by Medtronic, used three of the company's devices (CoreValve, Evolut R, Evolut Pro) in the TAVR arm.

Two-Year SURTAVI Data Presented for Medtronic's CoreValve Platform in Intermediate-Risk Patients

March 17, 2017—Medtronic plc announced the first presentation of clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial, at ACC.17, the American College of Cardiology's 66th annual scientific session in Washington, DC.

EVOLUT Low-Risk Trial Compares TAVR and SAVR Outcomes at 4 Years

October 24, 2023—Four-year data from the EVOLUT trial found that patients who have severe aortic stenosis and are at low surgical risk had better valve performance and demonstrated clinical outcomes diverging with transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR).

FDA Approves Low-Risk Indication for Medtronic's Evolut TAVR System

August 16, 2019–Medtronic announced FDA approval of the company's Evolut transcatheter aortic valve replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality.

Annual Outcomes From the STS/ACC TVT Registry Evaluate Transcatheter Valve Therapy

November 30, 2015—David R. Holmes, Jr, MD, et al published a report of the annual outcomes of transcatheter valve therapy (TVT) from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry, which is available online ahead of print in Annals of Thoracic Surgery and Journal of the American College of Cardiology.

Medtronic Evolut TAVR System Receives Approval for Low-Risk Indication in Europe

June 22, 2020—Medtronic announced CE Mark approval and the European launch of the Evolut system for transcatheter aortic valve replacement (TAVR) in patients with severe native aortic stenosis who are at a low risk of surgical mortality.

Medtronic’s Evolut TAVR System Evaluated in Low-Risk Patients at 5 Years

March 30, 2025—Medtronic announced 5-year outcomes from the Evolut Low-Risk Trial.

Medtronic's CoreValve TAVR System Widens Advantage Over Surgery at 2 Years


March 15, 2015—Two-year data show a continued survival advantage for transcatheter aortic valve replacement (TAVR) with the CoreValve self-expanding device (Medtronic plc) over standard surgery in high-risk patients with severe aortic stenosis, according to research presented at the 64th annual scientific session of the American College of Cardiology (ACC) in San Diego, California.  Medtronic, the sponsor of the trial, advised that the CoreValve system was approved by the US Food and Drug Administration in 2014 for patients at extreme risk and high risk for surgery.